Jan Mathisen, MD
Neurology with Special Qualifications in Child Neurology · Birmingham, ALNPI 1275687766
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,337 of the $8,262 with a category attached, or 64.6%. 17 manufacturers reported payments, led by Neurelis, Inc. at 40.5% of the total. Reporting peaked in 2020 at $3,157 and has fallen 65.2% since, to $1,099 in 2025.
Across 145 payments — averaging $56.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$3K
- UCB, Inc.$2K
- Jazz Pharmaceuticals Inc.$1K
- Greenwich Biosciences, Inc.$484
- SK Life Science, Inc.$246
- Catalyst Pharmaceuticals, Inc.$127
- plus $605 from 11 others
What the payments were for
- Speaking & faculty fees$2,92535%
- Food & beverage$5,33765%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 24 | $3,344 |
| UCB, Inc. | 61 | $2,376 |
| Jazz Pharmaceuticals Inc. | 17 | $1,080 |
| Greenwich Biosciences, Inc. | 8 | $484 |
| SK Life Science, Inc. | 8 | $246 |
| Catalyst Pharmaceuticals, Inc. | 6 | $127 |
| Sunovion Pharmaceuticals Inc. | 1 | $125 |
| Biocodex, Inc. | 1 | $103 |
| Acadia Pharmaceuticals Inc | 4 | $89 |
| Eisai Inc. | 4 | $82 |
| Zogenix Inc. | 3 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Livanova USA, Inc. | 2 | $37 |
| Pyros Pharmaceuticals, Inc. | 1 | $30 |
| Immedica Pharma US, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,262 in reported general payments places this provider in the 65th percentile of 24 neurology with special qualifications in child neurology providers in Alabama.
See all neurology with special qualifications in child neurology providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 38 | $191,189 |
| BriviactBrivaracetam | 16 | $33,276 |
| Oxtellar XrOxcarbazepine | 13 | $30,530 |
| XcopriCenobamate | 22 | $25,322 |
| Depakote ErDivalproex Sodium | 46 | $21,326 |
| Rufinamide | 23 | $17,814 |
| Lacosamide | 76 | $15,239 |
| ValtocoDiazepam | 13 | $8,801 |
| Aripiprazole | 35 | $6,595 |
| Clobazam | 35 | $5,972 |
| Diazepam | 93 | $4,662 |
| Risperidone | 203 | $3,801 |
| Lisdexamfetamine Dimesylate | 17 | $3,293 |
| Lamotrigine ErLamotrigine | 22 | $3,253 |
| Methylphenidate ErMethylphenidate Hcl | 28 | $2,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $2,376 | $33,27616 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $17 | $30,53013 claims |
| SK Life Science, Inc.Xcopri | $246 | $25,32222 claims |
| Neurelis, Inc.Valtoco | $3,344 | $8,80113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 24 neurology with special qualifications in child neurology providers in Alabama.
Other neurology with special qualifications in child neurology in Birmingham
- Alyssa ReddyBirmingham$68K
- Alan PercyBirmingham$51K
- Michael LopezBirmingham$22K
- Elizabeth BebinBirmingham$15K
- Amitha AnanthBirmingham$10K
- Monisha GoyalBirmingham$8K
- Kathryn LalorBirmingham$3K
- Pongkiat KankirawatanaBirmingham$2K
- Emily GantzBirmingham$1K
- Katherine ThaggardBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.